Lung cell therapy shows promise in IPF trial

NCT ID NCT06081621

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a new cell therapy called REGEND001 for people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. The therapy uses special lung cells to try to repair damaged tissue. In this phase 2 trial, 23 participants received either the cell therapy or a placebo to see if it could improve lung function over 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Renji Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, 200127, China

  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, 200025, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, 361021, China